
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PHO | Oslo | NOK | Real-time | |
0IMT | London | NOK | Real-time | |
PHONOK | Stockholm | NOK | Real-time |
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf’s System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Name | Age | Since | Title |
---|---|---|---|
Anne Worsøe | - | - | Director |
Dylan Hallerberg | - | 2023 | Independent Chairman |
Neal D. Shore | - | - | Independent Director |
Ghizlane Tagmouti | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review